Multiple Myeloma
Multiple myeloma is a cancer of the plasma cells found in bone marrow and it constitutes 1 percent of total cancer incidence worldwide. The disease is responsible for 2 percent of total cancer-related deaths worldwide.
OWC conducted pre-clinical studies at Sheba Hospital in Tel Aviv on multiple myeloma (MM) cell lines and CD138+ MM cells isolated from patients. These studies showed that the combination of CBD/THC at certain ratios had synergistic cytotoxic activity on these cell lines. This combined effect of the compounds was significantly higher compared to CBD or THC alone.
CBD/THC decreased mitochondrial membrane potential and induced apoptosis by activating caspases 8, caspase 3 and poly (ADP-ribose) polymerase. In addition, the combination of CBD and THC increased the expression level of beclin-1 and light chain 3-II form proteins indicating activation of autophagy.
Furthermore, the combination of CBD/THC together with bortezomib, carfilzomib, dexamethasone and doxorubicin increased MM cell death significantly as compared to each of these drugs or CBD/THC alone.
The company has also shown that a combination of CBD and THC was able to decrease the survival of cancerous cells in an in vitro mouse model and had a synergistic effect with known anti-MM drugs. These pre-clinical studies provided a rationale for further development of a CBD/THC combination therapy for treating patients with MM.
Subject to achieving research milestones, the company will submit an application to the FDA for an orphan disease designation
RELATED ARTICLES
OWC Pharmaceutical Research Corp Successfully Tests Unique, Innovative Delivery Formulation Aimed at Multiple Myeloma Therapy.
Our newly developed, highly concentrated formulation, OWC-1808, was administered in vivo for the first time and was found to be safe and tolerable. This formulation will allow the delivery of very high doses of CBD and THC with exceptional bioavailability, and will be directed initially at our ongoing program for treating Multiple Myeloma.
OWC Pharmaceutical Research Corp. to report progress in clinical trials for ointment care for skin diseases.
The first ever safety study of cannabis-based topical ointment, conducted at Sheba Academic Medical Center, is close to completion as the last healthy volunteer started the treatment three weeks ago. The study is expected to be completed by the end of December 2018.
OWC Pharmaceutical Research Corp Completes Development of Next Generation Orally-Disintegrating Tablet.
OWC Pharmaceutical has completed the pre-clinical development of its next generation, orally-disintegrating tablet containing cannabis extract with specific amounts of the cannabinoids tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”). The tablet is targeted at different indications and will be available in various ratios of THC to CBD and various doses of these actives.
